Codexis Reports 102% Revenue Growth to $15.2 Million in Latest Quarter

Codexis, Inc. reported significant financial improvements in its latest quarterly results, with total revenues reaching $15.2 million for the three months ended March 31, 2026, a 102% increase from $7.5 million in the same period last year. This growth was driven by a substantial rise in research and development revenue, which surged to $8.1 million from $1.5 million, primarily due to the recognition of deferred revenue from a licensing agreement with Merck. Product revenue also saw a 19% increase, totaling $7.2 million, attributed to fluctuations in customer manufacturing schedules and clinical trial timelines.

The company's operating expenses decreased by 17% to $23.3 million, down from $28.0 million in the prior year. Notably, costs associated with product revenue fell by 24%, while selling, general, and administrative expenses dropped by 21%. As a result, Codexis reported a loss from operations of $8.0 million, a significant improvement compared to the $20.5 million loss recorded in the same quarter of 2025. The net loss for the quarter was $8.7 million, or $0.10 per share, compared to a net loss of $20.7 million, or $0.25 per share, in the previous year.

Operationally, Codexis has made strides in its strategic initiatives, particularly in its ECO Synthesis manufacturing platform, which focuses on enhancing the production of RNA interference therapeutics. The company has entered partnerships with three large-scale contract development and manufacturing organizations to evaluate its enzymatic tools and processes, with expectations to advance at least one partnership in 2026. Additionally, Codexis has maintained a steady employee headcount, with 90,894 shares of common stock outstanding as of March 31, 2026.

Despite the positive financial performance, Codexis reported a decrease in cash and cash equivalents, which fell to $36.6 million from $50.8 million at the end of 2025. The company continues to manage its liquidity carefully, with a focus on funding ongoing operations and capital expenditures. Looking ahead, Codexis anticipates that its existing cash, combined with expected revenues from product sales and research collaborations, will provide sufficient funds for its operational needs over the next 12 months. However, the company acknowledges the potential need for additional capital to support its growth initiatives and technology development.